Luxembourg Parkinson’s study -comprehensive baseline analysis of Parkinson’s disease and atypical parkinsonism

peer reviewed ; Background: Deep phenotyping of Parkinson’s disease (PD) is essential to investigate this fastest-growing neurodegenerative disorder. Since 2015, over 800 individuals with PD and atypical parkinsonism along with more than 800 control subjects have been recruited in the frame of the observational, monocentric, nation-wide, longitudinal-prospective Luxembourg Parkinson’s study.Objective: To profile the baseline dataset and to explore risk factors, comorbidities and clinical profiles associated with PD, atypical parkinsonism and controls.Methods: Epidemiological and clinical chara... Mehr ...

Verfasser: PAVELKA, Lukas
RAWAL, Rajesh
GHOSH, Soumyabrata
PAULY, Claire
PAULY, Laure
HANFF, Anne-Marie
KOLBER, Pierre Luc
JONSDOTTIR, Sonja
MCINTYRE, Deborah
AZAIZ, Kheira
THIRY, Elodie
Vilasboas, Liliana
SOBOLEVA, Ekaterina
GIRAITIS, Marijus
TSURKALENKO, Olena
SAPIENZA, Stefano
DIEDERICH, Nico
KLUCKEN, Jochen
GLAAB, Enrico
Aguayo, Gloria A.
Jubal, Eduardo Rosales
PERQUIN, Magali
Vaillant, Michel
MAY, Patrick
Gantenbein, Manon
SATAGOPAM, Venkata
KRÜGER, Rejko
NCER-PD Consortium
Dokumenttyp: journal article
Erscheinungsdatum: 2023
Verlag/Hrsg.: Frontiers Media SA
Schlagwörter: Neurology (clinical) / Neurology / Parkinson's disease / Parkinsonism / Clinical data / Luxembourg / Epidemiology / Human health sciences / Public health / health care sciences & services / Sciences de la santé humaine / Neurologie / Santé publique / services médicaux & soins de santé
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-27522540
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://orbilu.uni.lu/handle/10993/59073

peer reviewed ; Background: Deep phenotyping of Parkinson’s disease (PD) is essential to investigate this fastest-growing neurodegenerative disorder. Since 2015, over 800 individuals with PD and atypical parkinsonism along with more than 800 control subjects have been recruited in the frame of the observational, monocentric, nation-wide, longitudinal-prospective Luxembourg Parkinson’s study.Objective: To profile the baseline dataset and to explore risk factors, comorbidities and clinical profiles associated with PD, atypical parkinsonism and controls.Methods: Epidemiological and clinical characteristics of all 1,648 participants divided in disease and control groups were investigated. Then, a cross-sectional group comparison was performed between the three largest groups: PD, progressive supranuclear palsy (PSP) and controls. Subsequently, multiple linear and logistic regression models were fitted adjusting for confounders.ResultsThe mean (SD) age at onset (AAO) of PD was 62.3 (11.8) years with 15% early onset (AAO < 50 years), mean disease duration 4.90 (5.16) years, male sex 66.5% and mean MDS-UPDRS III 35.2 (16.3). For PSP, the respective values were: 67.6 (8.2) years, all PSP with AAO > 50 years, 2.80 (2.62) years, 62.7% and 53.3 (19.5). The highest frequency of hyposmia was detected in PD followed by PSP and controls (72.9%; 53.2%; 14.7%), challenging the use of hyposmia as discriminating feature in PD vs. PSP. Alcohol abstinence was significantly higher in PD than controls (17.6 vs. 12.9%, p = 0.003).Conclusion: Luxembourg Parkinson’s study constitutes a valuable resource to strengthen the understanding of complex traits in the aforementioned neurodegenerative disorders. It corroborated several previously observed clinical profiles, and provided insight on frequency of hyposmia in PSP and dietary habits, such as alcohol abstinence in PD.Clinical trial registration: clinicaltrials.gov, NCT05266872. ; 3. Good health and well-being